Patient Enrollment Begins for Australian Trial

May 11, 2020

Patient Enrollment Begins for Australian Trial

Mesoblast, a Melbourne-based biotech company, began enrolling up to 300 patients for a randomized, controlled study of its stem cell therapy remestemcel-L for the treatment of COVID-19. Over 20 hospitals will participate in the study, which is anticipated to last 3-4 months. Yourway is equipped to handle and transport sensitive clinical trial materials, including cell and gene therapies.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit

November 17-18, 2025
Revere Hotel Boston Common

Schedule a Meeting

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Media

Articles

Mitigating Risk in Drug Development: The Strategic Role of Phase I Research Units

Open chat

Hello! How can I help you?